|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2014-2-7 19:02 编辑
The Future
Individualized treatment strategy for HbeAg negative:
First line PEG-IFN and week 12 stopping rule
The cost effectiveness of the management of HBeAg negative chronic Heaptitis B could be improved significantly by a shift toward a response guide first line therapy with PEF-IFN followed by a switch to NAs in patients meeting weeK-12 HBVDNA/HBsAg stopping rule.
Decisional algorithms based on HBsAg and HBVDNA kinetics will be added to AASLD, EASL, APASL guidelines
Stopping rules validated according to HBsAg level and on treatment decrease, genotype specific, will be applied to the PEG-IFN treatment, whatever the HBe status
HBsAg threshold, probably genotype specific, will be identified and will allow to end NAs treatment without risk of relapses.
个体化治疗策略HBeAg阴性：
第一行PEG-IFN和12周停止规则
的HBeAg阴性慢性Heaptitis B中的管理的成本效益可能是由一个转向的响应指南第一线治疗PEF-干扰素其次是在满足星期-12 HBVDNA/ HBsAg的停止规则的病人切换到NAs
显著改善。
基于HBsAg和HBVDNA动力学决策性的算法将被添加到AASLD，EASL，APASL指南
根据HBsAg的水平，并减少治疗停止验证规则，特定基因型，将被施加到PEG-IFN治疗，无论HBe的状态
HBsAg的门槛，可能具体的基因型，将确定，并允许停止NAs治疗无复发的风险
|
|
发表于 2014-2-5 18:09
